Semaglutide and CRP in obesity: 2026 data

A systematic review and meta-analysis published in the International Journal of Obesity on 29 August 2026 asked a specific question: what does subcutaneous semaglutide actually do to body weight and inflammatory markers in people who are overweight or obese but do not have type 2 diabetes^[1]? The answer, pooled across nine randomized controlled trials and 6,239 participants, is that the drug produces clinically meaningful reductions in both.

The headline numbers: semaglutide reduced percentage body weight from baseline by a mean of 12.04% (95% CI: 13.08 to 11.00) compared with placebo^[1]. Waist circumference fell by a mean of 9.36 cm. C-reactive protein (CRP), a widely used marker of systemic inflammation, dropped by 40.90% (95% CI: 46.37 to 35.42) relative to placebo. Serious adverse events did not differ significantly between the semaglutide and placebo arms (risk ratio 1.12, 95% CI: 0.76 to 1.65).

What the review covered and how it was done

The authors, Milluzzo and colleagues at the University of Catania, searched multiple databases for randomized controlled trials comparing subcutaneous semaglutide to placebo in adults with overweight or obesity who did not have type 2 diabetes^[1]. Nine trials met inclusion criteria, enrolling a combined 6,239 participants. The primary endpoints were percentage body weight change and CRP change. Secondary endpoints included waist circumference.

The pool of available trials has expanded considerably since earlier meta-analyses on this question, in part because the STEP programme generated multiple large, well-controlled datasets in non-diabetic populations. The STEP UP trial of semaglutide 7.2 mg, published in the Lancet Diabetes and Endocrinology in November 2025, contributed data showing 18.7% mean weight reduction at the higher dose compared with 15.6% on the standard 2.4 mg dose and 3.9% on placebo^[4]. The Milluzzo meta-analysis flagged this as the upper end of the current evidence base, and noted that extended research at these higher doses is warranted.

What CRP reduction actually means

CRP is an acute-phase protein produced by the liver in response to inflammation. Elevated levels in people with obesity are not incidental: excess adipose tissue, particularly visceral fat, secretes inflammatory cytokines that drive chronically raised CRP. This low-grade inflammation is one proposed mechanism linking obesity to cardiovascular disease^[3].

The SELECT trial, a cardiovascular outcomes study that enrolled 17,604 non-diabetic adults with overweight or obesity and pre-existing cardiovascular disease, found that semaglutide 2.4 mg weekly reduced the composite of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke by 20% (hazard ratio 0.80, 95% CI: 0.72 to 0.90) over a mean follow-up of just over three years^[3]. Whether the anti-inflammatory effect observed in the Milluzzo meta-analysis partially explains that cardiovascular benefit is a question the field has not yet settled.

The 40.90% CRP reduction is a pooled estimate across trials of varying duration and dose. It does not mean every participant saw that magnitude of change. Trial-level heterogeneity, differences in baseline CRP, and dose-response variation all affect what any individual might experience.

Where STEP 1 sits in this picture

The foundational non-diabetic obesity trial remains STEP 1, published in the New England Journal of Medicine in March 2021. In 1,961 adults with a BMI of 30 or above (or 27 with at least one weight-related comorbidity), semaglutide 2.4 mg weekly produced a mean 14.9% body weight reduction at 68 weeks versus 2.4% on placebo^[2]. 86.4% of participants on semaglutide achieved at least 5% weight loss, compared with 31.5% on placebo.

The Milluzzo meta-analysis synthesizes STEP 1 alongside newer trials, which is why its pooled weight-loss figure of 12.04% sits below the STEP 1 headline: the pool includes trials at different doses, durations, and baseline characteristics. A pooled mean is not the expected outcome for any individual person. For a deeper look at what the trial programme shows over time, see semaglutide long-term weight loss: what the trial data shows.

What the review does not tell us

Several things remain open. First, the review is restricted to randomized controlled trial data; it does not capture real-world populations, where adherence, dose titration patterns, and baseline comorbidities differ substantially. Second, most included trials were 68 to 72 weeks in length. Whether the CRP reduction is durable at two or three years is not established.

Third, CRP is one inflammatory marker. The review did not pool data on TNF-alpha, IL-6, or other cytokines, so the scope of any anti-inflammatory effect is incompletely characterized. Fourth, the review covers only subcutaneous semaglutide; oral semaglutide data is not included. For more background on how semaglutide acts at the receptor level, see how semaglutide works.

What this means if you are reading about semaglutide

This review adds to a growing body of evidence that subcutaneous semaglutide produces clinically meaningful weight loss and reduces a key inflammatory marker in non-diabetic adults with overweight or obesity. It does not address how to obtain semaglutide, what dose is appropriate for any given person, or whether the cardiovascular benefits observed in SELECT apply to someone without pre-existing cardiovascular disease. Those are clinical questions for a healthcare provider. For regulatory status by country, see the semaglutide peptide page.

Medical disclaimer: This article is for educational and journalistic purposes only and does not constitute medical advice. Semaglutide is a prescription medicine in most jurisdictions. Always consult a qualified healthcare professional before using any medicine. PeptideMethods.com does not sell, distribute, or facilitate the sale of any pharmaceutical product.